Karyopharm Therapeutics Company Profile (NASDAQ:KPTI)

About Karyopharm Therapeutics

Karyopharm Therapeutics logoKaryopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. It lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. Its product pipeline includes Verdinexor (KPT-335), an oral SINE compound; KPT-9274, a dual p21-activated kinase 4 (PAK4)/Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, and KPT-350, a compound in development for the treatment of neurological disorders.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KPTI
  • CUSIP:
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $9.37
  • 200 Day Moving Average: $8.42
  • 52-Week Range: $4.83 - $19.41
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.83
  • P/E Growth: 0.23
  • Market Cap: $308.43M
  • Outstanding Shares: 35,989,000
  • Beta: 4.26
  • Return on Equity: -62.24%
  • Return on Assets: -57.21%
  • Current Ratio: 8.00%
  • Quick Ratio: 8.00%
Additional Links:
Companies Related to Karyopharm Therapeutics:

Analyst Ratings

Consensus Ratings for Karyopharm Therapeutics (NASDAQ:KPTI) (?)
Ratings Breakdown: 1 Sell Rating, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.82)
Consensus Price Target: $16.21 (89.18% upside)

Analysts' Ratings History for Karyopharm Therapeutics (NASDAQ:KPTI)
DateFirmActionRatingPrice TargetDetails
10/7/2016Leerink SwannReiterated RatingOutperform$18.00View Rating Details
9/8/2016Jefferies GroupReiterated RatingBuy$12.00View Rating Details
9/8/2016HC WainwrightBoost Price TargetBuy$15.00 -> $16.00View Rating Details
9/6/2016Robert W. BairdReiterated RatingPositive$16.00View Rating Details
8/30/2016S&P Equity ResearchLower Price Target$9.06 -> $7.55View Rating Details
8/6/2016Canaccord GenuitySet Price TargetBuy$20.00View Rating Details
8/4/2016WedbushReiterated RatingOutperform$14.00View Rating Details
5/27/2016Raymond James Financial Inc.Initiated CoverageOutperform$13.00View Rating Details
3/15/2016Bank of America Corp.DowngradeNeutral -> Underperform$26.00 -> $11.00View Rating Details
3/14/2016JPMorgan Chase & Co.Lower Price TargetOverweight$20.00 -> $19.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$58.00 -> $28.00View Rating Details
12/22/2015FBR & CoReiterated RatingBuy$20.00View Rating Details
8/12/2015MLV & Co.Lower Price TargetBuy$54.00 -> $42.00View Rating Details
3/17/2015Oppenheimer Holdings Inc.Reiterated RatingOutperform$53.00View Rating Details
11/5/2014Barrington ResearchInitiated CoverageBuy$54.00View Rating Details
(Data available from 10/21/2014 forward)


Earnings History for Karyopharm Therapeutics (NASDAQ:KPTI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($0.76)($0.84)ViewN/AView Earnings Details
5/9/2016Q116($0.74)($0.75)ViewN/AView Earnings Details
3/14/2016Q415($0.82)($0.81)ViewListenView Earnings Details
11/9/2015Q315($0.87)($0.85)ViewListenView Earnings Details
8/10/2015Q215($0.77)($0.92)ViewListenView Earnings Details
5/11/2015Q115($0.75)($0.74)ViewListenView Earnings Details
3/16/2015Q414($0.66)($0.79)ViewListenView Earnings Details
11/10/2014Q314($0.52)($0.61)ViewN/AView Earnings Details
8/7/2014Q214($0.50)($1.02)ViewN/AView Earnings Details
5/7/2014($0.47)($0.46)ViewN/AView Earnings Details
3/5/2014($0.34)($2.00)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Karyopharm Therapeutics (NASDAQ:KPTI)
Current Year EPS Consensus Estimate: $-3.22 EPS
Next Year EPS Consensus Estimate: $-3.03 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.79)($0.73)($0.75)
Q2 20163($0.76)($0.73)($0.74)
Q3 20163($0.83)($0.75)($0.79)
Q4 20163($0.84)($0.76)($0.80)
Q1 20171($0.62)($0.62)($0.62)
Q2 20171($0.60)($0.60)($0.60)
Q3 20171($0.62)($0.62)($0.62)
Q4 20171($0.64)($0.64)($0.64)
(Data provided by Zacks Investment Research)


Dividend History for Karyopharm Therapeutics (NASDAQ:KPTI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Karyopharm Therapeutics (NASDAQ:KPTI)
Insider Ownership Percentage: 14.79%
Institutional Ownership Percentage: 55.68%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/23/2016Ltd ChioneMajor ShareholderSell18,824$8.03$151,156.72View SEC Filing  
6/13/2016Ltd ChioneMajor ShareholderSell7,074$8.51$60,199.74View SEC Filing  
6/9/2016Ltd ChioneMajor ShareholderSell45,541$9.21$419,432.61View SEC Filing  
6/7/2016Ltd ChioneMajor ShareholderSell40,000$9.24$369,600.00View SEC Filing  
6/2/2016Ltd ChioneMajor ShareholderSell17,855$9.65$172,300.75View SEC Filing  
6/1/2016Ltd ChioneMajor ShareholderSell74,664$9.61$717,521.04View SEC Filing  
5/31/2016Ltd ChioneMajor ShareholderSell17,096$9.66$165,147.36View SEC Filing  
5/27/2016Ltd ChioneMajor ShareholderSell40,000$9.58$383,200.00View SEC Filing  
5/26/2016Ltd ChioneMajor ShareholderSell46,122$9.73$448,767.06View SEC Filing  
5/23/2016Ltd ChioneMajor ShareholderSell93,932$8.54$802,179.28View SEC Filing  
5/18/2016Ltd ChioneMajor ShareholderSell63,800$8.15$519,970.00View SEC Filing  
5/16/2016Ltd ChioneMajor ShareholderSell10,400$8.01$83,304.00View SEC Filing  
5/11/2016Ltd ChioneMajor ShareholderSell31,868$8.24$262,592.32View SEC Filing  
12/8/2015Mansoor Raza MirzaDirectorSell15,000$15.01$225,150.00View SEC Filing  
4/7/2015Ran FrenkelEVPBuy3,000$31.81$95,430.00View SEC Filing  
4/2/2015Barry E GreeneDirectorBuy3,000$29.31$87,930.00View SEC Filing  
4/2/2015Justin A RenzCFOBuy5,000$29.71$148,550.00View SEC Filing  
1/12/2015Deepika PakianathanDirectorBuy45,454$33.00$1,499,982.00View SEC Filing  
1/12/2015Michael KauffmanCEOSell50,000$33.00$1,650,000.00View SEC Filing  
1/12/2015Sharon ShachamInsiderSell25,000$33.00$825,000.00View SEC Filing  
12/2/2014Mansoor Raza MirzaDirectorSell10,000$43.52$435,200.00View SEC Filing  
12/1/2014Ltd ChioneMajor ShareholderSell278,115$41.92$11,658,580.80View SEC Filing  
11/25/2014Ltd ChioneMajor ShareholderSell242,800$42.40$10,294,720.00View SEC Filing  
11/19/2014Ltd ChioneMajor ShareholderSell65,968$40.09$2,644,657.12View SEC Filing  
11/12/2014Ltd ChioneMajor ShareholderSell164,100$42.83$7,028,403.00View SEC Filing  
11/11/2014Ltd ChioneMajor ShareholderSell54,100$42.51$2,299,791.00View SEC Filing  
11/10/2014Ltd ChioneMajor ShareholderSell65,000$43.40$2,821,000.00View SEC Filing  
11/10/2014Mansoor Raza MirzaDirectorSell5,000$45.05$225,250.00View SEC Filing  
11/6/2014Ltd ChioneMajor ShareholderSell272,784$42.11$11,486,934.24View SEC Filing  
10/29/2014Mansoor Raza MirzaDirectorSell3,500$40.05$140,175.00View SEC Filing  
9/26/2014Marcin CzernikMajor ShareholderSell50,000$42.54$2,127,000.00View SEC Filing  
9/24/2014Marcin CzernikMajor ShareholderSell22,498$40.32$907,119.36View SEC Filing  
9/18/2014Marcin CzernikMajor ShareholderSell12,347$40.24$496,843.28View SEC Filing  
9/17/2014Marcin CzernikMajor ShareholderSell9,569$40.26$385,247.94View SEC Filing  
9/12/2014Ltd ChioneMajor ShareholderSell4,312$41.12$177,309.44View SEC Filing  
9/8/2014Marcin CzernikMajor ShareholderSell35,666$39.92$1,423,786.72View SEC Filing  
9/4/2014Marcin CzernikMajor ShareholderSell12,795$38.07$487,105.65View SEC Filing  
8/27/2014Marcin CzernikMajor ShareholderSell43,699$38.80$1,695,521.20View SEC Filing  
8/25/2014Marcin CzernikMajor ShareholderSell4,389$38.08$167,133.12View SEC Filing  
8/15/2014Marcin CzernikMajor ShareholderSell8,027$39.11$313,935.97View SEC Filing  
8/11/2014Marcin CzernikMajor ShareholderSell36,979$37.30$1,379,316.70View SEC Filing  
7/30/2014Marcin CzernikMajor ShareholderSell21,570$36.20$780,834.00View SEC Filing  
7/29/2014Ltd ChioneMajor ShareholderSell30,000$35.20$1,056,000.00View SEC Filing  
7/23/2014Ltd PlioInsiderSell500,000$35.54$17,770,000.00View SEC Filing  
7/2/2014Michael KauffmanCEOSell200,000$42.50$8,500,000.00View SEC Filing  
6/18/2014Sharon ShachamInsiderSell20,000$41.76$835,200.00View SEC Filing  
6/17/2014Michael KauffmanCEOSell20,000$41.76$835,200.00View SEC Filing  
5/23/2014Deepika PakianathanDirectorBuy114,419$26.18$2,995,489.42View SEC Filing  
5/13/2014Paul BrannellySVPBuy1,000$28.06$28,060.00View SEC Filing  
11/12/2013Deepika PakianathanDirectorBuy312,500$16.00$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Karyopharm Therapeutics (NASDAQ:KPTI)
News IconBroker Roundup For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - The De Soto Edge (NASDAQ:KPTI)
www.desotoedge.com - October 21 at 9:15 AM
News IconRating Sentiment Watching: How Analysts Feel About Karyopharm ... - MoneyMakingArticles (NASDAQ:KPTI)
www.mmahotstuff.com - October 19 at 6:12 PM
News Icon47 Shares of Karyopharm Therapeutics Inc. (KPTI) are sold by ... - DailyQuint (NASDAQ:KPTI)
dailyquint.com - October 17 at 10:51 AM
capitalcube.com logoKaryopharm Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : KPTI-US : October 17, 2016 (NASDAQ:KPTI)
www.capitalcube.com - October 17 at 10:51 AM
News IconAnalysts Take Aim At This Stock's Earnings Estimates: Karyopharm ... - CSZ News (NASDAQ:KPTI)
cincysportszone.com - October 14 at 5:43 PM
News IconStock Cascading Downward Before Open: Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) - CSZ News (NASDAQ:KPTI)
cincysportszone.com - October 13 at 5:53 PM
istreetwire.com logo3 Stocks in Focus: Karyopharm Therapeutics, Inc. (KPTI), Marathon Oil Corporation (MRO), Marvell Technology Group ... - iStreetWire (NASDAQ:KPTI)
istreetwire.com - October 13 at 5:53 PM
finance.yahoo.com logoKaryopharm to Present at the 15th Annual BIO Investor Forum (NASDAQ:KPTI)
finance.yahoo.com - October 11 at 6:05 PM
investornewswire.com logoKaryopharm Therapeutics Inc. (NASDAQ:KPTI) :EPS Projection At $-0.69 - Investor Newswire (NASDAQ:KPTI)
www.investornewswire.com - October 7 at 10:53 AM
News IconAre Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Shares Heading Higher? - Recall News (NASDAQ:KPTI)
www.automobile-recalls.net - October 7 at 10:53 AM
investingnews.com logoKaryopharm to Present Updated SIGN Phase 2 Clinical Data at ESMO (NASDAQ:KPTI)
investingnews.com - October 5 at 5:46 PM
streetinsider.com logoKaryopharm Therapeutics (KPTI) Announces Presentation of Selinexor Phase 2 Data; Lower Adverse Effects Noted (NASDAQ:KPTI)
www.streetinsider.com - October 5 at 5:45 PM
streetinsider.com logoKaryopharm Therapeutics (KPTI) Announces Presentation of ... - StreetInsider.com (NASDAQ:KPTI)
www.streetinsider.com - October 5 at 11:06 AM
finance.yahoo.com logoKaryopharm to Present Updated SIGN Phase 2 Clinical Data at European Society of Medical Oncology 2016 Annual Meeting (NASDAQ:KPTI)
finance.yahoo.com - October 5 at 11:06 AM
finance.yahoo.com logo6:21 am Karyopharm Therapeutics will present updated clinical data from its ongoing Phase 2 study of selinexor at the ESMO 2016 being held October 7-11 (NASDAQ:KPTI)
finance.yahoo.com - October 5 at 11:06 AM
realistinvestor.com logoKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Is Expected To Post EPS Of $-0.69 - RealistInvestor.com (NASDAQ:KPTI)
www.realistinvestor.com - October 3 at 5:32 PM
4-traders.com logoKaryopharm Therapeutics : Publishes Preclinical Data in Nature Demonstrating Selinexors Potential in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC) (NASDAQ:KPTI)
www.4-traders.com - September 30 at 6:02 PM
News IconCurrent Price Targets For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - NewsDen (NASDAQ:KPTI)
newsden.net - September 30 at 11:01 AM
smarteranalyst.com logoCompany Update (NASDAQ:KPTI): Karyopharm Therapeutics Inc Publishes Preclinical and Phase 1 Clinical Data for ... - Smarter Analyst (NASDAQ:KPTI)
www.smarteranalyst.com - September 30 at 11:01 AM
4-traders.com logoKaryopharm Therapeutics : Publishes Preclinical Data in Nature Demonstrating Selinexor's Potential in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC) (NASDAQ:KPTI)
www.4-traders.com - September 29 at 5:48 PM
streetinsider.com logoKaryopharm Therapeutics (KPTI) Announces Publication of Strong Preclinical Data on Selinexor in NSCLC (NASDAQ:KPTI)
www.streetinsider.com - September 29 at 5:48 PM
streetinsider.com logoKaryopharm Therapeutics (KPTI) Announces Publication of Strong ... - StreetInsider.com (NASDAQ:KPTI)
www.streetinsider.com - September 29 at 10:53 AM
publicnow.com logoKaryopharm Publishes Preclinical Data in Nature Demonstrating Selinexor's Potential in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC) (NASDAQ:KPTI)
www.publicnow.com - September 29 at 10:52 AM
News IconKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Latest Broker Coverage - NewsDen (NASDAQ:KPTI)
newsden.net - September 28 at 5:39 PM
streetinsider.com logoKaryopharm Therapeutics (KPTI) Announces Publication of Selinexor Phase 1 Data in XPO1 Inhibition - StreetInsider.com (NASDAQ:KPTI)
www.streetinsider.com - September 28 at 5:39 PM
4-traders.com logoKaryopharm Publishes Preclinical and Phase 1 Clinical Data for Selinexor in Ovarian Cancer in Clinical Cancer Research Publication (NASDAQ:KPTI)
www.4-traders.com - September 28 at 10:45 AM
News IconKaryopharm Therapeutics Inc (KPTI) Given “Outperform” Rating at Wedbush - DailyQuint (NASDAQ:KPTI)
dailyquint.com - September 22 at 5:39 PM
News IconKaryopharm Therapeutics Incorporated (NASDAQ:KPTI) Short Interest Increased By 3.25% - Post News (NASDAQ:KPTI)
www.kentuckypostnews.com - September 22 at 9:03 AM
News IconShares in Focus: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Earnings & Targets Update - Frisco Fastball (NASDAQ:KPTI)
friscofastball.com - September 21 at 4:06 PM
News IconCould Karyopharm Therapeutics Inc Rise Even More? The Stock ... - Chester News (NASDAQ:KPTI)
www.chesterindependent.com - September 15 at 3:46 PM
capitalcube.com logoETF’s with exposure to Karyopharm Therapeutics, Inc. : September 14, 2016 (NASDAQ:KPTI)
www.capitalcube.com - September 14 at 5:55 PM
News IconEarnings According to Analysts for Karyopharm Therapeutics Inc. (NASDAQ:KPTI)? - Frisco Fastball (NASDAQ:KPTI)
friscofastball.com - September 14 at 10:04 AM
publicnow.com logoKaryopharm Appoints Humphrey A.R. Gardner MD, FCAP as Senior Vice President, Clinical Development (NASDAQ:KPTI)
www.publicnow.com - September 12 at 10:34 AM
News IconPlacing Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Shares Under the Microscope - Post News (NASDAQ:KPTI)
www.kentuckypostnews.com - September 8 at 5:44 PM
News IconHealthcare Top Losers- Tonix Pharmaceuticals (NASDAQ:TNXP), Karyopharm Therapeutics (NASDAQ:KPTI) - Seneca Globe (NASDAQ:KPTI)
www.senecaglobe.com - September 8 at 5:44 PM
fool.com logoWhy Karyopharm Therapeutics Stock Is Falling Today (NASDAQ:KPTI)
www.fool.com - September 6 at 5:51 PM
rttnews.com logoD-Day For KPTI Today (NASDAQ:KPTI)
www.rttnews.com - September 6 at 10:38 AM
streetinsider.com logoKaryopharm Therapeutics (KPTI) Announces Top-Line Selinexor Phase 2b Data in Multiple Myeloma (NASDAQ:KPTI)
www.streetinsider.com - September 6 at 10:38 AM
biz.yahoo.com logoKARYOPHARM THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:KPTI)
biz.yahoo.com - September 6 at 10:38 AM
thestreet.com logoKaryopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug (NASDAQ:KPTI)
www.thestreet.com - September 6 at 10:38 AM
publicnow.com logoKaryopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple Myeloma (NASDAQ:KPTI)
www.publicnow.com - September 6 at 10:38 AM
News IconStock Dipping Down in Today's Session: Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) - Post News (NASDAQ:KPTI)
www.kentuckypostnews.com - September 2 at 5:51 PM
News IconExpert Analysts Sentiments for: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) , Richmont Mines, Inc. (NYSEMKT:RIC) - Wall Street Times (press release) (NASDAQ:KPTI)
www.wallstreetnews24.com - September 2 at 10:41 AM
News IconWhat Do Analysts Think Of Karyopharm Therapeutics Inc. (NASDAQ:KPTI)? (NASDAQ:KPTI)
10thousandcouples.com - September 1 at 8:55 AM
insidermonkey.com logoLooking Ahead To The Karyopharm Therapeutics Inc (KPTI) MM Data (NASDAQ:KPTI)
www.insidermonkey.com - September 1 at 8:55 AM
News IconKaryopharm Therapeutics Inc (NASDAQ:KPTI): Institutional Investor Sentiment Up to 1.54 (NASDAQ:KPTI)
www.crcconnection.com - September 1 at 8:55 AM
capitalcube.com logoKaryopharm Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : KPTI-US : August 31, 2016 (NASDAQ:KPTI)
www.capitalcube.com - August 31 at 10:41 AM
fool.com logoWhy Karyopharm Therapeutics Inc Shares Are Soaring 31% Today (NASDAQ:KPTI)
www.fool.com - August 30 at 5:54 PM
thestreet.com logoMarkets Very Sluggish as August Nears an End (NASDAQ:KPTI)
realmoney.thestreet.com - August 30 at 5:54 PM
realistinvestor.com logoKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Is Expected To Post EPS Of $-0.7 - RealistInvestor.com (NASDAQ:KPTI)
www.realistinvestor.com - August 30 at 9:08 AM


Karyopharm Therapeutics (NASDAQ:KPTI) Chart for Friday, October, 21, 2016

Last Updated on 10/21/2016 by MarketBeat.com Staff